HAE Company Profile and Key Details

Q: Who are the executives of HAE?

Mr. Christopher A. SimonChief Executive Officer, Pres & DirectorMs. Laurie A. MillerSenior Vice President & Chief HR OfficerMs. Olga GuyetteSenior Director of Investor RelationsMr. James C. D'Arecca CPAChief Financial Officer, Executive Vice President & Financial OfficerCarla BurigattoVice President of CommunicationsMr. Josep Lluis LlorensExecutive Vice President of Global Manufacturing & Supply ChainMr. Stewart W. StrongPres of Global HospitalMr. Francis TanSenior Vice President of Corporation Devel. & PlanningMs. Farris Maryanne MaunsellVice President, Chief Accounting Officer & Principal Accounting OfficerMr. Rajeev VarmaSenior Vice President of Strategy & Corporation Devel.Ms. Anila LingamneniExecutive Vice President & Chief Technology OfficerMs. Michelle L. BasilExecutive Vice President, Gen. Counsel & Sec.

NYSE : HAE

Haemonetics

$57.69

-1.65-2.78%

At Close 4:00 PM

72.03

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Haemonetics Corporation (HAE) stock declined over -2.78%, trading at $57.69 on NYSE, down from the previous close of $59.34. The stock opened at $58.92, fluctuating between $56.99 and $59.64 in the recent session.

Stock Snapshot

59.34

Prev. Close

2.7B

Market Cap

56.985

Day Low

15.89

P/E Ratio

3.63

EPS (TTM)

2.54

Cash Flow per Share

58.92

Open

46.81M

Number of Shares

59.64

Day High

98.8%

Free Float in %

18.58

Book Value

1.11M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 09, 2026	59.00	59.65	56.99	57.69	1.49M
Feb 06, 2026	65.00	65.95	59.13	59.34	1.77M
Feb 05, 2026	65.00	67.63	63.99	65.02	1.53M
Feb 04, 2026	64.82	66.99	64.29	65.95	1.56M
Feb 03, 2026	65.18	66.56	64.51	64.86	765.42K
Feb 02, 2026	66.73	66.85	65.32	65.78	800.82K
Jan 30, 2026	65.69	66.68	64.99	66.66	1.01M
Jan 29, 2026	66.06	66.41	64.75	65.96	710.91K
Jan 28, 2026	67.83	67.94	65.86	66.06	705.16K
Jan 27, 2026	68.08	68.56	67.63	67.87	731.94K
Jan 26, 2026	68.80	68.91	68.03	68.37	734.31K
Jan 23, 2026	70.00	70.62	68.56	68.82	581.99K
Jan 22, 2026	69.80	71.79	69.80	70.02	1.21M
Jan 21, 2026	70.73	73.00	69.78	70.11	1.52M
Jan 20, 2026	71.02	71.48	70.02	70.10	639.28K
Jan 16, 2026	73.73	74.39	71.61	72.17	1.03M
Jan 15, 2026	75.51	76.11	73.36	74.00	956.19K
Jan 14, 2026	78.90	78.90	75.28	75.73	876.37K
Jan 13, 2026	82.00	82.57	76.98	78.82	1.12M
Jan 12, 2026	82.34	83.39	81.64	82.92	513.76K

Contact Details

Boston, MA 02110

United States

https://www.haemonetics.com 781 848 7100

About Company

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Stock Peers

RMD

4.33+1.59%

ResMed Inc.$275.96 WST

-0.02-0.01%

West Pharmaceutical Services, Inc.$248.93 BDX

-2.63-1.25%

Becton, Dickinson and Company$207.39 ATR

4.16+3.10%

AptarGroup, Inc.$138.47 TFX

-2.21-2.04%

Teleflex Incorporated$106.21 ALC

-0.39-0.49%

Alcon Inc.$78.44 WRBY

-1.38-5.41%

Warby Parker Inc.$24.14 BAX

Baxter International Inc.$21.73 BLCO

-0.09-0.53%

Bausch + Lomb Corporation$16.91 STVN

0.6+3.87%

Stevanato Group S.p.A.$16.10

Company Overview

Haemonetics Corporation (NYSE:HAE) closed at $57.69 USD, losing -$1.65 (-2.78%) from the previous close of $59.34. The stock is currently mid-range between its 52-week high and low $47.32 and $87.32. With a market capitalization of about $2.70 billion, Haemonetics Corporation is classified as a mid-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 867.74 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Haemonetics Corporation operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Christopher A. Simon, the company employs approximately 3,657 people and listed since May 10, 1991. Haemonetics Corporation, a healthcare company, provides medical products and solutions.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -16.16%, SMA50 -24.69%, SMA200 -13.14%). The stock’s 14-day RSI is 16.77 (weak momentum), while the ATR of 2.6 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -33.93% below its high and over 21.93% above its low. Average 10-day trading volume of 1.28 million shares is significantly above the 3-month average of 842.18 thousand, indicating heightened recent market interest.

Valuation Metrics

Haemonetics Corporation trades at a P/E ratio of 15.38, slightly below the S&P 500 average, with a price-to-sales ratio of 2.05 and a price-to-book ratio of 2.96 suggesting the stock is closer to book value. The P/FCF stands at 8.76, also above market averages.

Dividend & Fair Value

Haemonetics Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $188.41. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Haemonetics Corporation generated EPS of $3.64 over the past year. Five-year average earnings growth is 17.48%. Wall Street analysts project EPS growth of 9.07% annually over the next five years. The latest quarter delivered EPS of $1.27. The next quarter is forecast at $1.27. Next year's EPS is expected at $10.89. Analyst sentiment is bullish. Analyst rating data shows there are 14 Strong Buy ratings, 10 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $104.00 to $62.00. The high target offers 80.27% upside. The low target suggests 7.47% downside. The mean target is $84.50. This offers 46.47% upside. Haemonetics Corporation earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 13.39%. The prior quarter beat by 8.91%. Over the last six quarters, Apple has recorded several small beats. These include -27.77% in August 08, 2024.

Shareholding & Insider Activity

Haemonetics Corporation has 48.18 million shares outstanding. The public float is 47.60 million shares, elevated short interest at 8.49% of float. This equals 3.08 million shares. The short ratio is 5.65 days. Institutional investors hold 117.07% of the float. Insiders own 1.15%. Simon, Christopher holds 213.72 thousand shares, MEELIA RICHARD J has 32.05 thousand shares and Basil Michelle L has 31.26 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Haemonetics generated $1.36B in revenue, or $26.82 per share. Gross margin was 57.21%, operating margin 16.30%, and net profit margin 12.32%. Returns are healthy, with ROA at 6.84% and ROE at 20.43%.
On valuation metrics, Haemonetics trades at a P/E of 15.38, P/S of 2.05 and P/B of 2.96. The current ratio is 1.75 and quick ratio is 1.15. Operationally, the company’s inventory turnover is 1.67 and cash conversion cycle is 239.66 days. Debt-to-equity is 1.34, supported by a cash flow-to-debt ratio of 0.28.

Quarterly Financial Highlights

For the quarter ended Mar 29, 2025, Haemonetics posted revenue of $1.36B, down slightly from $1.31B in the prior quarter. Gross profit was $778.55M (margin 57.21%). Operating income was $221.82M (margin 16.3%). Net income was$167.68M (EPS $3.31).
The company ended the quarter with $306.76M in cash and short-term investments, a total debt of $1.22B, and net debt of $918.03M. Total assets were $2.45B, with equity of $820.84M. Financials further reflected stability, with operating cash flow of $181.73M, free cash flow of $142.45M, and capital expenditures of - $39.28M.

Price Forecast & Outlook

Our AI price prediction model suggests that Haemonetics Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.65%, with price expected at $54.43 by February 20, 2026, within a range of $52.35 to $56.78 3-Month Outlook: Projected rise of 47.96%, reaching $85.36 by May 07, 2026, with a range of $82.25 to $88.76. 1-Year Outlook: Projected gain of 2.86%, with price at $59.34 by February 05, 2027, within a range of $56.21 to $62.37.

Key Takeaways

Haemonetics Corporation (NYSE:HAE) shares are down -12.54% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Haemonetics Corporation trading at a premium to the broader market with a P/E of 15.38. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $95.20, suggesting 65.02% upside. Our AI forecast model points to short-term weakness (-5.65% over two weeks), a medium-term rise (47.96% over three months), and a longer-term gain (2.86% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Haemonetics Corporation (HAE) stock price?

Haemonetics Corporation (NYSE: HAE) stock price is $57.69 in the last trading session. During the trading session, HAE stock reached the peak price of $59.64 while $56.99 was the lowest point it dropped to. The percentage change in HAE stock occurred in the recent session was -2.78% while the dollar amount for the price change in HAE stock was - $1.65.

HAE's industry and sector of operation?

The NYSE listed HAE is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Haemonetics Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HAE?

Mr. Christopher A. Simon
Chief Executive Officer, Pres & Director
Ms. Laurie A. Miller
Senior Vice President & Chief HR Officer
Ms. Olga Guyette
Senior Director of Investor Relations
Mr. James C. D'Arecca CPA
Chief Financial Officer, Executive Vice President & Financial Officer
Carla Burigatto
Vice President of Communications
Mr. Josep Lluis Llorens
Executive Vice President of Global Manufacturing & Supply Chain
Mr. Stewart W. Strong
Pres of Global Hospital
Mr. Francis Tan
Senior Vice President of Corporation Devel. & Planning
Ms. Farris Maryanne Maunsell
Vice President, Chief Accounting Officer & Principal Accounting Officer
Mr. Rajeev Varma
Senior Vice President of Strategy & Corporation Devel.
Ms. Anila Lingamneni
Executive Vice President & Chief Technology Officer
Ms. Michelle L. Basil
Executive Vice President, Gen. Counsel & Sec.

How HAE did perform over past 52-week?

HAE's closing price is 21.91% higher than its 52-week low of $47.32 where as its distance from 52-week high of $87.32 is -33.93%.

How many employees does HAE have?

Number of HAE employees currently stands at 3,657.

Link for HAE official website?

Official Website of HAE is: https://www.haemonetics.com

How do I contact HAE?

HAE could be contacted at phone 781 848 7100 and can also be accessed through its website. HAE operates from 125 Summer Street, Boston, MA 02110, United States.

How many shares of HAE are traded daily?

HAE stock volume for the day was 1.11M shares. The average number of HAE shares traded daily for last 3 months was 867.74K.

What is the market cap of HAE currently?

The market value of HAE currently stands at $2.70B with its latest stock price at $57.69 and 46.81M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	3657
Beta	0.28
Sales or Revenue	$1.36B
5Y Sales Change%	0.387%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Medical - Instruments & Supplies

HAE Company Profile and Key Details

Haemonetics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Valuation Metrics

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook